Clinical trial · Observational
Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution
Genomic Analysis in Localized or Locally Advanced Prostate Cancer. Identification of Biomarkers Predictive of Biochemical or Metastatic Recurrence
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Developing a genetic study on localized or locally advanced prostate cancer. The aim of the study is to identify genomic alteration predictive of metastatic recurrence in the context of primary heterogeneity, by using the next generation sequencing (NGS) techniques. Identifying such biomarkers may be useful to detect a higher relapse risk, and thus lower the mortality rate.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- case group
- description
- patients with biochemical recurrence and positive imaging (case group)
- label
- Control Group
- description
- patients without biochemical recurrence (control group)
Primary outcomes (1)
- measure
- The genetic alteration frequencies of TMPRSS2-ERG gene fusion
- timeFrame
- Baseline
Secondary outcomes (3)
- measure
- Frequency of amplification of proto-oncogenes (MYC, AR, PIK3CA),
- timeFrame
- Baseline
- measure
- Frequency of mutations or deletions of tumor suppressor genes (PTEN, TP53, NKX3-1),
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients managed by radical prostatectomy for prostate cancer between 2000 and 2016. * Follow up \> 6 years * Negative pre surgical extension assessment * Prognostic Grade Groups (OGG) III-IV-V * Biochemical recurrence defined by 2 consecutive PSA rises ≥ 0,2 ng/mL * Metastasis positive imaging Exclusion Criteria: * Neoadjuvant therapy * Follow up \< 6 years * Prognostic Grade Groups (PGG) I-II * Biochemical recurrence with metastasis negative imaging
References
Publications (0)
Data not yet available